DSM Pharmaceutical Products has signed a non-exclusive license agreement with Amgen providing access to its XD high cell density process patents. XD technology is a highly intensified cell culture process with typical titer achievement of 8-to-10 times higher than current standard biomanufacturing processes, according to the company. It is applicable for multiple biological products including proteins, fusion proteins and antibodies, as well as the full spectrum of mammalian cell systems. Financ...